EVAX
Income statement / Annual
Last year (2023), Evaxion Biotech A/S's total revenue was $73,000.00,
and the percentage change from the previous year is not available.
In 2023, Evaxion Biotech A/S's net income was -$22.13 M.
See Evaxion Biotech A/S,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
| Operating Revenue |
$73,000.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$112.00
|
$571,319.00
|
$343,452.00
|
$105,719.00
|
$80,984.00
|
$73,928.00
|
| Gross Profit |
$72,888.00
|
-$571,319.00
|
-$343,452.00
|
-$105,719.00
|
-$80,984.00
|
-$73,928.00
|
| Gross Profit Ratio |
1
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$11.92 M
|
$17.06 M
|
$19.58 M
|
$10.90 M
|
$8.22 M
|
$3.73 M
|
| General & Administrative Expenses |
$10.35 M
|
$8.21 M
|
$6.25 M
|
$5.67 M
|
$2.63 M
|
$1.88 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$10.35 M
|
$8.21 M
|
$6.25 M
|
$5.67 M
|
$2.63 M
|
$1.88 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$16,000.00
|
$15,000.00
|
| Operating Expenses |
$22.25 M
|
$25.26 M
|
$25.83 M
|
$16.57 M
|
$10.86 M
|
$5.63 M
|
| Cost And Expenses |
$22.27 M
|
$25.26 M
|
$25.83 M
|
$16.57 M
|
$10.86 M
|
$5.63 M
|
| Interest Income |
$154,000.00
|
$2.83 M
|
$2.04 M
|
$216,000.00
|
$9,000.00
|
$2,000.00
|
| Interest Expense |
$897,000.00
|
$1.51 M
|
$915,000.00
|
$223,000.00
|
$1.22 M
|
$698,000.00
|
| Depreciation & Amortization |
$615,946.00
|
$571,319.00
|
$343,452.00
|
$105,719.00
|
$80,984.00
|
$73,928.00
|
| EBITDA |
-$21.40 M |
-$22.58 M |
-$24.17 M |
-$16.46 M |
-$11.90 M |
-$6.18 M |
| EBITDA Ratio |
-293.19
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
-304.07
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
-$718,000.00
|
$1.32 M
|
$1.12 M
|
-$7,000.00
|
-$1.16 M
|
-$636,933.00
|
| Income Before Tax |
-$22.92 M
|
-$23.94 M
|
-$24.71 M
|
-$16.58 M
|
-$12.02 M
|
-$6.27 M
|
| Income Before Tax Ratio |
-313.9
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
-$791,215.00
|
-$772,000.00
|
-$178,000.00
|
-$1.56 M
|
-$825,000.00
|
-$735,000.00
|
| Net Income |
-$22.13 M
|
-$23.17 M
|
-$24.53 M
|
-$15.02 M
|
-$11.20 M
|
-$5.54 M
|
| Net Income Ratio |
-303.08
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-1.622 |
-1.96 |
-2.516 |
-1.854 |
-1.382 |
-0.576 |
| EPS Diluted |
-1.622 |
-1.96 |
-2.516 |
-1.854 |
-1.382 |
-0.576 |
| Weighted Average Shares Out |
$13.67 M
|
$11.82 M
|
$9.75 M
|
$8.10 M
|
$8.10 M
|
$9.60 M
|
| Weighted Average Shares Out Diluted |
$13.67 M
|
$11.82 M
|
$9.75 M
|
$8.10 M
|
$8.10 M
|
$9.60 M
|
| Link |
|
|
|
|
|
|
